PLX Protalix BioTherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1006281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.0%
TTM net income YoY281.0%
TTM EPS YoY200.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR24.6%
Margins
Gross margin71.2%
Operating margin29.8%
Net margin24.3%
FCF margin17.8%
EBITDA margin31.7%
Returns
ROE30.8%
ROA20.5%
ROIC (approx.)41.0%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets31.9%
Debt / equity0.00x
Current ratio3.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio3.0%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $52.74M | $53.40M |
| Cost of revenue | $26.99M | $24.32M |
| Gross profit | $25.75M | $29.08M |
| R&D expense | $19.57M | $12.97M |
| SG&A expense | $11.68M | $12.19M |
| Operating income | -$5.50M | $3.92M |
| Pretax income | -$5.61M | $4.15M |
| Income tax | $996,000 | $1.22M |
| Net income | -$6.60M | $2.93M |
| EBITDA | -$4.04M | $5.22M |
| EPS (basic) | -0.08 | 0.04 |
| EPS (diluted) | -0.08 | 0.04 |
| Weighted avg. shares (diluted) | 78.55M | 81.06M |
| Balance sheet | ||
| Cash & equivalents | $14.68M | $19.76M |
| Receivables | $8.84M | $2.91M |
| Inventory | $25.73M | $21.24M |
| Current assets | $66.67M | $60.08M |
| PP&E, net | $4.88M | $4.59M |
| Total assets | $82.35M | $73.42M |
| Current liabilities | $26.52M | $25.62M |
| Total liabilities | $34.12M | $30.21M |
| Shareholders' equity | $48.23M | $43.21M |
| Shares outstanding | 80.43M | 75.85M |
| Cash flow statement | ||
| Operating cash flow | -$11.99M | $8.67M |
| Capital expenditure | $1.64M | $1.28M |
| Free cash flow | -$13.63M | $7.39M |
| Investing cash flow | -$2.37M | $4.22M |
| Financing cash flow | $9.33M | -$16.79M |
| Depreciation & amortization | $1.47M | $1.30M |
| Stock-based compensation | $2.30M | $3.25M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.